French maritime pine bark treatment decelerates plaque development and improves spatial memory in Alzheimer's disease mice.

BACKGROUND Plant extracts are increasingly investigated as potential drugs against Alzheimer's disease (AD) and dementia in general. Pycnogenol is an extract from the bark of the French maritime pine (Pinus pinaster Aiton subsp. atlantica) with known anti-oxidative and neuroprotective effects. HYPOTHESIS/PURPOSE Pycnogenol is thought to improve cognitive functions in elderly. We wanted to investigate and quantify these effects in a model system of cerebral ß-amyloidosis/AD. STUDY DESIGN/METHODS This study experimentally assessed the effects of Pycnogenol on AD-related pathology in a ß-amyloidosis mouse model. APP-transgenic mice and controls were treated orally in a pre-onset and post-onset treatment paradigm. The effects of Pycnogenol were characterized by analysing ß-amyloid (Aß) plaques, number of neurons, glia coverage, myelination pattern, and cortical coverage with axons using immunohistochemistry. Aß levels were quantified using ELISA and gene expression levels of APP-processing enzymes ADAM10, BACE1 and IDE protein levels were determined by Western blot. Behavioural changes in circadian rhythm were monitored and spatial memory / cognition was assessed using a water maze test. RESULTS Pycnogenol significantly decreased the number of plaques in both treatment paradigms but did not alter levels of soluble Aß or the gene expression of APP-processing enzymes. The morphological analyses revealed no changes in the number of neurons, astrocytes, microglia, the myelination pattern, or the morphology of axons. Behavioural testing revealed an improvement of the spatial memory in the pre-onset treatment paradigm only. CONCLUSION Our results suggest to evaluate clinically a potential use of Pycnogenol in the prevention or in early stages of mild cognitive impairment (MCI) and AD.

[1]  B. Winblad,et al.  Cerebral ABC transporter-common mechanisms may modulate neurodegenerative diseases and depression in elderly subjects. , 2014, Archives of medical research.

[2]  G. Belcaro,et al.  Pycnogenol® improves cognitive function, attention, mental performance and specific professional skills in healthy professionals aged 35-55. , 2014, Journal of neurosurgical sciences.

[3]  Rui Liu,et al.  Total flavonoid extract from Dracoephalum moldavica L. attenuates &bgr;‐amyloid‐induced toxicity through anti‐amyloidogenesic and neurotrophic pathways , 2018, Life sciences.

[4]  Toshitaka Nagao,et al.  Plaque formation and the intraneuronal accumulation of β‐amyloid in Alzheimer's disease , 2017, Pathology international.

[5]  O. von Bohlen und Halbach,et al.  Accumulation of murine amyloid-β mimics early Alzheimer's disease. , 2015, Brain : a journal of neurology.

[6]  Paul J. Harrison,et al.  Searching for cognitive enhancement in the Morris water maze: better and worse performance in D‐amino acid oxidase knockout (Dao −/−) mice , 2016, The European journal of neuroscience.

[7]  Gregory A. Hickey,et al.  A limited role for microglia in antibody mediated plaque clearance in APP mice , 2007, Neurobiology of Disease.

[8]  C. Stewart,et al.  The effect of stress on the expression of the amyloid precursor protein in rat brain , 2008, Neuroscience Letters.

[9]  G. Belcaro,et al.  Pycnogenol® supplementation improves cognitive function, attention and mental performance in students. , 2011, Panminerva medica.

[10]  A. Kesselheim,et al.  The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. , 2017, The New England journal of medicine.

[11]  Ninoslav Mimica,et al.  Dementia: a public health priority , 2019 .

[12]  F. Schmitt,et al.  Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models , 2014, Front. Genet..

[13]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[14]  Hartwig Wolburg,et al.  Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology , 2006, EMBO reports.

[15]  J. Leza,et al.  Restraint stress increases neuroinflammation independently of amyloid β levels in amyloid precursor protein/PS1 transgenic mice , 2011, Journal of neurochemistry.

[16]  T. Brüning,et al.  Revisiting rodent models: Octodon degus as Alzheimer’s disease model? , 2016, Acta Neuropathologica Communications.

[17]  T. Brüning,et al.  Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer's disease. , 2011, Current Alzheimer research.

[18]  A. Onu,et al.  Pycnogenol® efficacy in the treatment of systemic lupus erythematosus patients , 2001, Phytotherapy research : PTR.

[19]  T. Brüning,et al.  Activation of Mitochondrial Complex II-Dependent Respiration Is Beneficial for α-Synucleinopathies , 2015, Molecular Neurobiology.

[20]  R. Palme,et al.  A less stressful alternative to oral gavage for pharmacological and toxicological studies in mice. , 2012, Toxicology and applied pharmacology.

[21]  Andreas Wree,et al.  Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice. , 2011, The Journal of clinical investigation.

[22]  H. Heinze,et al.  Mitochondrial DNA polymorphisms specifically modify cerebral β-amyloid proteostasis , 2012, Acta Neuropathologica.

[23]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[24]  S. Scheff,et al.  Cognitive assessment of pycnogenol therapy following traumatic brain injury , 2016, Neuroscience Letters.

[25]  G. Cole,et al.  The microglial phagocytic role with specific plaque types in the Alzheimer disease brain , 2004, Neurobiology of Aging.

[26]  J. Muchova,et al.  Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[27]  H. Heinze,et al.  Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. , 2013, Current Alzheimer research.

[28]  E. Balestrazzi,et al.  Treatment of vascular retinopathies with Pycnogenol® , 2001, Phytotherapy research : PTR.

[29]  B. Cullen,et al.  Update on Alzheimer's Disease Therapy and Prevention Strategies. , 2017, Annual review of medicine.

[30]  Thomas Brüning,et al.  Expression of endogenous mouse APP modulates β-amyloid deposition in hAPP-transgenic mice , 2017, Acta neuropathologica communications.

[31]  Suresh Govindaraghavan,et al.  Natural compounds and plant extracts as therapeutics against chronic inflammation in Alzheimer's disease--a translational perspective. , 2014, CNS & neurological disorders drug targets.

[32]  Leguo Zhang,et al.  Neuroprotective Effects of Pycnogenol Against Oxygen-Glucose Deprivation/Reoxygenation-Induced Injury in Primary Rat Astrocytes via NF-κB and ERK1/2 MAPK Pathways , 2017, Cellular Physiology and Biochemistry.

[33]  H. Heinze,et al.  Genomic background-related activation of microglia and reduced β-amyloidosis in a mouse model of Alzheimer's disease. , 2013, European journal of microbiology & immunology.

[34]  G. Belcaro,et al.  Pycnogenol® supplementation improves the control of irritable bowel syndrome symptoms. , 2018, Panminerva medica.

[35]  G. Belcaro,et al.  Efficacy of Pycnogenol® supplementation in remission phases of Sjögren syndrome. , 2018, Minerva cardioangiologica.

[36]  G. Belcaro,et al.  Behçet syndrome: effects of Pycnogenol® supplementation during regression phases. , 2018, Minerva cardioangiologica.

[37]  F. Haiss,et al.  Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance , 2008, The Journal of Neuroscience.

[38]  Marc Wortmann.  Dementia: a global health priority - highlights from an ADI and World Health Organization report , 2012, Alzheimer's Research & Therapy.

[39]  P. Azimzadeh,et al.  Neuroprotective Effects of Herbal Extract (Rosa canina, Tanacetum vulgare and Urtica dioica) on Rat Model of Sporadic Alzheimer’s Disease , 2016, Avicenna journal of medical biotechnology.

[40]  Q. Peng,et al.  Pycnogenol® protects neurons from amyloid-β peptide-induced apoptosis , 2002 .

[41]  R. Stelzmann,et al.  An english translation of alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde” , 1995, Clinical anatomy.

[42]  J. Silver,et al.  Astrocytes Regulate Microglial Phagocytosis of Senile Plaque Cores of Alzheimer's Disease , 1998, Experimental Neurology.

[43]  H. Neumann,et al.  Debris clearance by microglia: an essential link between degeneration and regeneration , 2008, Brain : a journal of neurology.

[44]  L. Downey,et al.  An examination of the effects of the antioxidant Pycnogenol® on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population , 2008, Journal of psychopharmacology.

[45]  M. Krohn,et al.  Sideritis spp. Extracts Enhance Memory and Learning in Alzheimer’s β-Amyloidosis Mouse Models and Aged C57Bl/6 Mice , 2016, Journal of Alzheimer's disease : JAD.

[46]  C. Pietrzik,et al.  Endothelial LRP1 – A Potential Target for the Treatment of Alzheimer’s Disease , 2017, Pharmaceutical Research.

[47]  C. Moussa.  Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease , 2017, Expert opinion on investigational drugs.

[48]  Z. Saddiqe,et al.  A review on biological, nutraceutical and clinical aspects of French maritime pine bark extract. , 2011, Journal of ethnopharmacology.